{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:49:37Z","timestamp":1790174977310,"version":"4.1.0"},"reference-count":24,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T00:00:00Z","timestamp":1540425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T00:00:00Z","timestamp":1540425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Technology &amp; Therapeutics"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Glycated hemoglobin (HbA1c) and measures of short-term glycemia do not fully capture daily patterns in plasma glucose dynamics. This study evaluated 24-h glycemic profiles in patients with type 2 diabetes (T2D) initiated on dapagliflozin treatment using continuous glucose monitoring (CGM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This randomized double-blind placebo-controlled multicenter parallel-design 4-week study compared dapagliflozin (10\u2009mg\/d;\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200950) with placebo (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200950) in adult patients with T2D uncontrolled (HbA1c 7.5%\u201310.5%) on either stable doses of metformin monotherapy (\u22651500\u2009mg\/d) or insulin (\u226530\u2009U\/d with or without up to two oral antidiabetes drugs). CGM was used to measure 24-h glycemic profiles for 7 days pretreatment and during week 4 of treatment. The primary outcome was change from baseline in 24-h mean glucose (MG) at week 4.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The 24-h MG decreased 18.2\u2009mg\/dL with dapagliflozin and increased 5.8\u2009mg\/dL with placebo (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.001). The proportion of time spent in the target glucose range (70\u2013180\u2009mg\/dL) increased significantly with dapagliflozin versus placebo (69.6% vs. 52.9%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.001), with a small (0.3%) increase in time spent in the hypoglycemic range (&lt;70\u2009mg\/dL), driven by those on background insulin therapy. Dapagliflozin reduced postprandial glucose and significantly decreased overall glucose variability. Few events of symptomatic hypoglycemia occurred. The most common adverse event was urinary tract infection (6% in each treatment arm).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Compared with placebo, dapagliflozin improved measures of glycemic control and variability as assessed by CGM. Glycemic improvements were more pronounced in the group on background metformin than those receiving basal insulin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/dia.2018.0052","type":"journal-article","created":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T14:53:29Z","timestamp":1537196009000},"page":"715-724","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":65,"title":["Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial"],"prefix":"10.1177","volume":"20","author":[{"given":"Robert R.","family":"Henry","sequence":"first","affiliation":[{"name":"University of California San Diego School of Medicine"},{"name":"VA San Diego Healthcare System"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poul","family":"Strange","sequence":"additional","affiliation":[{"name":"Integrated Medical Development, LLC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Medpace, Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Pettus","sequence":"additional","affiliation":[{"name":"University of California San Diego School of Medicine"},{"name":"VA San Diego Healthcare System"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Shi","sequence":"additional","affiliation":[{"name":"Integrated Medical Development, LLC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey B.","family":"Zhuplatov","sequence":"additional","affiliation":[{"name":"AstraZeneca"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traci","family":"Mansfield","sequence":"additional","affiliation":[{"name":"AstraZeneca"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Klein","sequence":"additional","affiliation":[{"name":"Medpace, Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arie","family":"Katz","sequence":"additional","affiliation":[{"name":"AstraZeneca"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,10,25]]},"reference":[{"key":"e_1_3_4_2_2","unstructured":"US Food and Drug Administration: Guidance for Industry. Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention. 2016. www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm071624.pdf (accessed August18 2016)."},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.29.02.06.dc05-1594"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2010.0230"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.5.6.592"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12713"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2014.38.6.449"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2015.05.007"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-2035"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.250"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12531"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.19.9.644"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/193229681100500408"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-S010"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010210"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-s241"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2010.0108"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.14.1681"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.2337\/db11-1478"},{"key":"e_1_3_4_20_2","unstructured":"AstraZeneca Pharmaceuticals LP: FARXIGA (dapagliflozin) tablets for oral use [Prescribing Information]. 2016. www.azpicentral.com\/farxiga\/pi_farxiga.pdf (accessed July13 2016)."},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-6-201203200-00003"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-014-0169-9"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141085"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1353"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60407-2"}],"container-title":["Diabetes Technology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/dia.2018.0052","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2018.0052","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2018.0052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:17:36Z","timestamp":1777400256000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/dia.2018.0052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,25]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1089\/dia.2018.0052"],"URL":"https:\/\/doi.org\/10.1089\/dia.2018.0052","relation":{},"ISSN":["1520-9156","1557-8593"],"issn-type":[{"value":"1520-9156","type":"print"},{"value":"1557-8593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,25]]}}}